Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Details Narrative)

v3.19.2
Stock-Based Compensation (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jun. 03, 2019
Apr. 02, 2019
Mar. 15, 2019
Jun. 30, 2019
May 31, 2019
Apr. 30, 2019
Feb. 28, 2018
Jun. 30, 2019
Mar. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Stock-based compensation expense               $ 388,363   $ 303,890 $ 847,049 $ 575,176
Lucid Diagnostics Inc [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Total unrecognized stock-based compensation expense       $ 200,000       200,000     $ 200,000  
Period for recognition of unrecognized compensation expense                     2 years 2 months 12 days  
Restricted Stock [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Stock-based compensation expense               $ 61,833     $ 82,444  
Employee Stock Purchase Plan [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of options granted   250,000                    
Vesting portion of stock   ESPP share purchase dates are April 1 and October 1, with an initial six month payroll deduction period of April 1, 2019 to September 30, 2019 with a corresponding share purchase date of October 1, 2019.                    
Purchase price per share percentage on ESPP plan   85.00%                    
2014 Long Term Incentive Equity Plan [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of common stock authorized       7,951,081       7,951,081     7,951,081  
Shares of common stock available for grant of stock options       2,648,406       2,648,406     2,648,406  
Number of shares granted outside       500,854       500,854     500,854  
Number of options granted                     1,825,000  
Exercise price per share                     $ 1  
Contractual term of stock options                     10 years  
Number of stock options forfeited           48,611         48,611  
Weighted average remaining contractual term of stock options outstanding                     8 years 7 months 6 days  
Weighted average remaining contractual term of stock options vested and exercisable                     7 years 9 months 18 days  
Total unrecognized stock-based compensation expense       $ 1,700,000       $ 1,700,000     $ 1,700,000  
Period for recognition of unrecognized compensation expense                     1 year 6 months  
2014 Long Term Incentive Equity Plan [Member] | Restricted Stock [Member] | Employment Agreement [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Vesting portion of stock     Annual basis, commencing March 15, 2020 and ending March 15, 2022                  
Number of restricted stock award granted     700,000                  
Number of restricted stock award granted, value     $ 742,000                  
2014 Long Term Incentive Equity Plan [Member] | Non-Executive Members of Board of Directors [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of options granted                 800,000      
Exercise price per share                 $ 1.00      
Vesting portion of stock                 Quarterly basis commencing March 31, 2019 and ending December 31, 2021      
2014 Long Term Incentive Equity Plan [Member] | Employees [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of options granted                     950,000  
Vesting portion of stock                     Quarterly basis commencing March 31, 2019 and ending December 31, 2021  
Weighted average fair value of stock options                     $ 1.90 $ 1.96
2014 Long Term Incentive Equity Plan [Member] | Non-employee Consultant [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of options granted         25,000              
Exercise price per share         $ 1.10              
Vesting portion of stock         Quarterly basis commencing June 30, 2019 and ending March 31, 2022              
2014 Long Term Incentive Equity Plan [Member] | New Hire Employee [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of options granted       50,000                
Exercise price per share       $ 1.08                
Vesting portion of stock       Quarterly basis commencing June 30, 2019 and ending March 31, 2022                
2014 Long Term Incentive Equity Plan [Member] | Non-employees [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Weighted average fair value of stock options                     $ 0.93 $ 1.23
2014 Long Term Incentive Equity Plan [Member] | Non-employees [Member] | Lucid Diagnostics Inc [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Stock-based compensation expense               4,202   3,633 $ 8,305 $ 3,633
2018 Long Term Incentive Equity Plan [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Total unrecognized stock-based compensation expense       $ 700,000       $ 700,000     $ 700,000  
Period for recognition of unrecognized compensation expense                     2 years 8 months 12 days  
2018 Long Term Incentive Equity Plan [Member] | Lucid Diagnostics Inc [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of common stock authorized       2,000,000       2,000,000     2,000,000  
Shares of common stock available for grant of stock options       1,525,000       1,525,000     1,525,000  
Number of options granted                     300,000  
Weighted average remaining contractual term of stock options outstanding                     9 years 3 months 19 days  
Weighted average remaining contractual term of stock options vested and exercisable                     9 years 3 months 19 days  
Expected dividend yield                     $ 0.00  
2018 Long Term Incentive Equity Plan [Member] | Non-employees [Member] | Lucid Diagnostics Inc [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Stock-based compensation expense               $ 28,555   $ 8,277 $ 133,058 $ 8,277
2018 Long-Term Incentive Equity Plan [Member] | Vesting Immediately [Member] | Lucid Diagnostics Inc [Member] | February 18, 2019 [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of options granted                     400,000  
Exercise price per share                     $ 1.00  
Vesting portion of stock                     Vesting immediately  
Weighted average remaining contractual term of stock options outstanding                     10 years  
2018 Long-Term Incentive Equity Plan [Member] | Employees [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of options granted 100,000           300,000          
Exercise price per share             $ 1.00          
Vesting portion of stock             Vesting immediately          
2018 Long-Term Incentive Equity Plan [Member] | Employees [Member] | Vesting Immediately [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of options granted             200,000          
2018 Long-Term Incentive Equity Plan [Member] | Employees [Member] | Vesting on a Quarterly Basis [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                        
Number of options granted             100,000